Article

Heidelberg Engineering expands Spectralis product line

Heidelberg Engineering GmbH expands its line of Spectralis retinal imaging products by adding a more economical two-mode, spectral domain-optical coherence tomography (SD-OCT) technology. The expanded family now consists of Spectralis OCT (two modes); Spectralis HRA (five modes); and Spectralis HRA+OCT (six modes).

Heidelberg Engineering GmbH expands its line of Spectralis retinal imaging products by adding a more economical two-mode, spectral domain-optical coherence tomography (SD-OCT) technology. The expanded family now consists of Spectralis OCT (two modes); Spectralis HRA (five modes); and Spectralis HRA+OCT (six modes).

Spectralis OCT offers two imaging modes (SD-OCT and infrared), while the Spectralis HRA+OCT includes four additional imaging modes (autofluorescence, red-free imaging, fluorescein angiography, and ICG angiography). The new model shares three key features with the earlier version: 40,000 A-scans per second, TruTrack eye-tracking technology, and Heidelberg noise reduction (HNR) for image clarity.

The Spectralis instrument captures the OCT cross-sectional scan under constant guidance of one of five fundus imaging modalities. This helps ensure image registration and enables the instruments to track change precisely over time, an advantage over the technical limitations of time-domain OCT, according to the company. In addition, HNR technology significantly improves image quality by eliminating unwanted optical noise in both fundus and OCT images.

Shipment of the product is expected to begin this summer, according to the company.

For more information, visit Heidelberg Engineering at Booth 1541.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.